Trial Profile
Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms OPTkIMA
- 20 Jul 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 20 Jul 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 21 Apr 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.